These findings highlighted that WSF treatment indeed attenuated the NAFLD and inflammation in the liver across the TLR4/NF-κB/COX-2 pathway, consistent with the results obtained above by the bioinformatics and molecular docking. The gene discussed is PTGS2; the disease is metabolic dysfunction-associated steatotic liver disease.